Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
Phase 1/2 Clinical trial of CD34-positive cell transplantation for patients with fracture nonunion was successfully performed. However, more effective way should be explored. Therefore, we examined 2 new strategies for this treatment. The first results proved that transplantation of AteloGene with Lnk si RNA contributed to ealry healing of mouse fracture model. The second results proved that ex-vivo expanded CD34-positive cells with key growth factors improved the efficacy by in vitro expansion culture and in vivo xenotransplantation model (human cell-immunodeficient rat).
|